^
    Back
    Association details:
    Biomarker:TA-MUC1 positive
    Cancer:Ovarian Cancer
    Drug:PankoMab-GEX (gatipotuzumab) (MUC1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

    Excerpt:
    ...Histologically-confirmed, TA-MUC1-positive, recurrent epithelial ovarian, or fallopian-tube cancer or primary peritoneal cancer with high-grade (Grade 2 or 3) serous features or a serous component 3....
    Trial ID:
    NCT01899599
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Open
    Title:

    Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

    Published date:
    12/15/2021
    Excerpt:
    Overall, 216 patients were randomized to gatipotuzumab (n  =  151) or placebo (n  =  65). Median PFS with gatipotuzumab was 3.5 months as compared with 3.5 months with placebo (hazard ratio 0.96, 95% confidence interval 0.69-1.33, P  =  0.80). Gatipotuzumab switch maintenance therapy does not improve outcome in TA-MUC1-positive ovarian cancer patients.
    DOI:
    https://doi.org/10.1016/j.esmoop.2021.100311
    Trial ID:
    NCT01899599